Iron and Chronic Kidney Disease: Still a Challenge
暂无分享,去创建一个
[1] C. Kovesdy,et al. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. , 2020, Journal of the American Society of Nephrology : JASN.
[2] L. Silvestri,et al. Iron metabolism and iron disorders revisited in the hepcidin era , 2020, Haematologica.
[3] Celena B. Peters,et al. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. , 2019, Kidney international.
[4] D. Swinkels,et al. Unraveling Hepcidin Plasma Protein Binding: Evidence from Peritoneal Equilibration Testing , 2019, Pharmaceuticals.
[5] C. Jacquelinet,et al. Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated , 2019, Clinical kidney journal.
[6] T. Ganz,et al. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease. , 2019, Advances in chronic kidney disease.
[7] D. Witcher,et al. Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease , 2019, British journal of clinical pharmacology.
[8] C. Zoccali,et al. Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study , 2019, Journal of clinical medicine.
[9] D. Swinkels,et al. First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis , 2019, PloS one.
[10] I. Macdougall,et al. Effects of Molidustat in the Treatment of Anemia in CKD. , 2018, Clinical journal of the American Society of Nephrology : CJASN.
[11] Nupur K. Das,et al. Hepatic hepcidin/intestinal HIF-2&agr; axis maintains iron absorption during iron deficiency and overload , 2018, The Journal of clinical investigation.
[12] S. Taylor,et al. Erythroferrone inhibits the induction of hepcidin by BMP6. , 2018, Blood.
[13] I. Nolte,et al. Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease , 2018, BMC Nephrology.
[14] T. Abe,et al. Crossroads of metabolism and CKD. , 2018, Kidney international.
[15] T. Ganz,et al. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] C. Camaschella,et al. Advances in understanding iron metabolism and its crosstalk with erythropoiesis , 2018, British journal of haematology.
[17] C. Ahn,et al. Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease , 2018, Scientific Reports.
[18] T. Ganz,et al. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease , 2018, Haematologica.
[19] T. Tamaki,et al. The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[20] K. Uhlig,et al. Hemoglobin response to ferric citrate in patients with nondialysis‐dependent chronic kidney disease and iron deficiency anemia , 2018, American journal of hematology.
[21] S. Fishbane,et al. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. , 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] Gurinder K. Singh,et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[23] P. Fu,et al. Hypoxia Induced Factor in Chronic Kidney Disease: Friend or Foe? , 2018, Front. Med..
[24] I. Macdougall. Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions , 2017, Clinical kidney journal.
[25] Jodie L Babitt,et al. Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice. , 2017, Blood.
[26] C. Ahn,et al. Serum hepcidin may be a novel uremic toxin, which might be related to erythropoietin resistance , 2017, Scientific Reports.
[27] K. Uhlig,et al. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. , 2017, Journal of the American Society of Nephrology : JASN.
[28] Jodie L Babitt,et al. Overview of iron metabolism in health and disease , 2017, Hemodialysis international. International Symposium on Home Hemodialysis.
[29] J. Lewis,et al. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis . , 2017, Clinical nephrology.
[30] I. Macdougall,et al. Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients , 2017, American Journal of Nephrology.
[31] V. Haase,et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. , 2016, Kidney international.
[32] M. Wolf,et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. , 2016, Kidney international.
[33] G. Navis,et al. Iron deficiency, anemia, and mortality in renal transplant recipients , 2016, Transplant international : official journal of the European Society for Organ Transplantation.
[34] James E. Novak,et al. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. , 2016, Clinical journal of the American Society of Nephrology : CJASN.
[35] S. Hemmerich,et al. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. , 2016, Journal of the American Society of Nephrology : JASN.
[36] A. Rastogi,et al. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. , 2016, Journal of the American Society of Nephrology : JASN.
[37] Toshinori Yamamoto,et al. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis , 2016, PloS one.
[38] L. Nilsson,et al. Effect of a More Permeable Dialysis Membrane on ESA Resistance in Hemodialysis Patients - A Pilot Investigation , 2015, Blood Purification.
[39] M. Wolf,et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production , 2015, Kidney international.
[40] T. Okado,et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD‐ROUTE study , 2015, Nephrology.
[41] I. Slotki,et al. The Labile Side of Iron Supplementation in CKD. , 2015, Journal of the American Society of Nephrology : JASN.
[42] M. Wolf,et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[43] C. Tetta,et al. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[44] Jodie L Babitt,et al. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[45] M. Stauffer,et al. Prevalence of Anemia in Chronic Kidney Disease in the United States , 2014, PloS one.
[46] C. Peyssonnaux,et al. The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. , 2013, Blood.
[47] Herbert Y. Lin,et al. Mechanisms of anemia in CKD. , 2012, Journal of the American Society of Nephrology : JASN.
[48] B. Haraldsson,et al. Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration , 2012, Nephron Extra.
[49] C. Hong,et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. , 2011, Blood.
[50] P. Subramanian,et al. Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2. , 2011, Cell metabolism.
[51] G. Sapkota,et al. The specificities of small molecule inhibitors of the TGFß and BMP pathways. , 2011, Cellular signalling.
[52] D. Scadden,et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. , 2011, Blood.
[53] T. Ganz,et al. Detection, evaluation, and management of iron-restricted erythropoiesis. , 2010, Blood.
[54] K. Yoshizaki,et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. , 2010, Blood.
[55] S. Lonial,et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. , 2010, Journal of Clinical Oncology.
[56] T. Ganz,et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[57] S. Bachmann,et al. Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization. , 2010, Kidney international.
[58] J. Małyszko,et al. Type of Renal Replacement Therapy and Residual Renal Function May Affect Prohepcidin and Hepcidin , 2009, Renal failure.
[59] S. Aronoff,et al. The prevalence of anemia in patients with chronic kidney disease , 2004, Current medical research and opinion.
[60] Jodie L Babitt,et al. Ironing out the cross talk between FGF23 and inflammation. , 2017, American journal of physiology. Renal physiology.
[61] T. Eleftheriadis,et al. Kynurenine, by activating aryl hydrocarbon receptor, decreases erythropoietin and increases hepcidin production in HepG2 cells: A new mechanism for anemia of inflammation. , 2016, Experimental hematology.
[62] V. Haase. Regulation of erythropoiesis by hypoxia-inducible factors. , 2013, Blood reviews.